Durgical
EN
Open the app

Anaemia of kidney disease: low EPO, iron first, then ESAs

  • Treatment and support

Failing kidneys stop calling for red cells. Fixing iron first, then replacing the signal, relieves tiredness; pushing the count to normal brings strokes.

Updated

What it is

The anaemia of chronic kidney disease (CKD) is a normocytic, normochromic anaemia with low reticulocytes. The main cause is too little erythropoietin (EPO) from the damaged kidney for the degree of anaemia, made worse by iron deficiency (absolute from blood loss, or functional because inflammation and high hepcidin lock iron away), shorter red cell survival, B12 or folate deficiency and severe hyperparathyroidism. It becomes common as kidney function falls and is almost universal on dialysis. Treatment is by principle: correct iron and other deficiencies first, then add an erythropoiesis-stimulating agent (ESA) when anaemia persists, aiming to relieve symptoms and avoid transfusion rather than to reach a normal haemoglobin.

What to know

  • CKD anaemia is a diagnosis of exclusion: iron deficiency, bleeding, B12 or folate deficiency, haemolysis and myeloma must be looked for first.
  • An EPO level is rarely useful: it is often 'normal', which is inappropriately low for the anaemia.
  • Iron: oral iron is usually tried first in CKD not on dialysis; intravenous iron is preferred on haemodialysis, where blood is lost at each session.
  • ESAs (epoetin, darbepoetin and longer-acting forms) replace the missing signal; HIF prolyl hydroxylase inhibitors are oral drugs that make the body raise its own EPO, where approved.
  • Trials that aimed for a normal haemoglobin with ESAs showed more stroke, hypertension, vascular access thrombosis and cardiovascular events, without better survival.
  • Avoid transfusion when possible in transplant candidates: each transfusion can create HLA antibodies that make a kidney harder to match.

How it is done (and why)

  1. Confirm the pattern: normocytic anaemia with low reticulocytes in a patient with reduced kidney function.
  2. Exclude other causes: iron studies, B12, folate, a search for blood loss, and a paraprotein screen when myeloma is possible.
  3. Replace iron first when ferritin or transferrin saturation is low; recheck, because some patients need nothing more.
  4. Persistent symptomatic anaemia with iron replete: consider an ESA after weighing stroke, cancer and blood pressure risks.
  5. Titrate to relieve symptoms and avoid transfusion, not to normalise; reduce or pause when the haemoglobin rises fast or high.
  6. Poor response: look for iron deficiency, infection or inflammation, hyperparathyroidism, inadequate dialysis, bleeding and, rarely, anti-EPO antibodies.

Why the haemoglobin will not rise on an ESA

Cause of poor responseClueWhat to do
Iron deficiency (absolute or functional)Low ferritin or low transferrin saturationReplace iron, usually intravenously on dialysis
Inflammation or infectionHigh CRP, infected access or foot ulcerTreat the cause; response returns
Blood lossIron keeps falling, positive stool testLook for a bleeding source, review antithrombotics
Severe hyperparathyroidism or inadequate dialysisHigh PTH, poor clearanceCorrect mineral-bone disorder, optimise dialysis
Pure red cell aplasia from anti-EPO antibodiesSudden severe anaemia, near-zero reticulocytesStop the ESA, test for antibodies, refer to haematology

Risks and precautions

  • Risks of ESAs: hypertension, seizures in a fast rise, thrombosis of the dialysis access, stroke, and possible tumour growth in patients with active cancer.
  • Patients with a history of stroke or active cancer need a frank discussion before an ESA, and the lowest effective exposure.
  • Intravenous iron can cause hypersensitivity reactions; it is given where resuscitation is available, and avoided during active infection.
  • A kidney transplant usually corrects the anaemia as the new kidney makes EPO.

Monitoring and next step

  • Before starting: full count, reticulocytes, ferritin, transferrin saturation, B12, folate; consider serum protein electrophoresis.
  • On iron: recheck iron studies to avoid both deficiency and overload.
  • On an ESA: haemoglobin regularly, more often after starting or changing; act on a fast rise.
  • Poor response: iron studies, CRP, PTH, dialysis adequacy, a bleeding search and reticulocytes; refer if reticulocytes are near zero.

Common traps

  • Starting an ESA before checking iron: the marrow cannot respond without iron and the dose escalates needlessly
  • Aiming for a normal haemoglobin on an ESA: higher targets brought more stroke and clotting without longer life
  • Calling every anaemia in CKD renal anaemia: bleeding, myeloma and B12 deficiency are common in the same patients
  • Trusting a normal ferritin as proof of enough iron in dialysis: inflammation raises ferritin while the iron available to the marrow (transferrin saturation) stays low

Test yourself

Think of the answer, then tap the question to see it.

A haemodialysis patient on an ESA has a falling haemoglobin, ferritin above the normal range and a low transferrin saturation. What is the most likely problem?

Functional iron deficiency: inflammation and high hepcidin raise ferritin but trap iron, so the marrow is short of iron; intravenous iron and a search for inflammation help.

Why should an ESA not be used to push the haemoglobin into the normal range in CKD?

Trials targeting normal values found more strokes, hypertension, access thrombosis and cardiovascular events without better survival, so the aim is symptom relief and avoiding transfusion.

A patient with stage 4 CKD on an ESA for a year suddenly needs transfusions and has near-zero reticulocytes with normal white cells and platelets. What should be done?

Suspect pure red cell aplasia from anti-EPO antibodies: stop the ESA, test for the antibodies and refer to haematology.

Why is transfusion avoided where possible in a young patient waiting for a kidney transplant?

Transfused cells can sensitise the patient to HLA antigens, raising antibodies that make finding a compatible kidney harder and raise the risk of rejection.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Anemia of Chronic Kidney Disease (StatPearls (NCBI Bookshelf), 2024); Anemia in Chronic Kidney Disease (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2026); Erythropoietin test: MedlinePlus Medical Encyclopedia (MedlinePlus, US National Library of Medicine, 2025).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.